Events
Shareholders approve new name which better reflects the Company’s ambition to deliver best in class therapies for back of the eye disorders
MagForce AG today announced its participation in nine upcoming scientific and investor conferences in the second half of 2018
The U.S. FDA announced a new pilot program aimed at stimulating the use of complex innovative clinical trial designs for drugs and biologics. Announced on Wednesday, August 29, the pilot program will continue through September 30, 2022.
Changes are coming to the way 23andMe does business. The company will no longer provide “outside app developers” access to the company’s raw genetic data, CNBC reported this morning.
As Brexit creeps closer and closer, the British government, as well as pharmaceutical companies and the European Medicines Agency, are preparing contingency plans for dealing with the possibility that healthcare-related companies will not have contracts in place in time.
The U.S. Food and Drug Administration has posted new draft guidance that will guide drug and medical device manufacturers that aim to develop treatments for “the underlying pathophysiology and structural progression” of osteoarthritis (OA).
Torque Therapeutics, a biotech company in Cambridge, Massachusetts, announced its high-efficiency T-cell manufacturing process called Slipstream.
In March, San Diego-based Orexigen Therapeutics filed for bankruptcy. Back in April, Orexigen entered into an asset purchase deal with Nalpropion Pharmaceuticals to sell most of its assets, subject to court approval.
Genentech and Horizon Pharma were the only two biopharma companies that made People’s 2018 list of “50 Companies That Care,” a list that highlights how a company makes a difference in the lives of its employees, as well as the communities those companies call home.
Forty years ago, Louise Brown was born on July 25. She was the first so-called “test tube baby,” born through in vitro fertilization (IVF).
PRESS RELEASES